Robeco Institutional Asset Management B.V. trimmed its position in shares of Kenvue Inc. (NYSE:KVUE – Free Report) by 51.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 100,515 shares of the company’s stock after selling 105,590 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Kenvue were worth $2,146,000 at the end of the most recent quarter.
Several other institutional investors also recently bought and sold shares of KVUE. Northwestern Mutual Wealth Management Co. increased its position in shares of Kenvue by 13.7% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 62,687 shares of the company’s stock worth $1,140,000 after acquiring an additional 7,564 shares during the period. B. Riley Wealth Advisors Inc. increased its holdings in Kenvue by 7.2% during the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 27,278 shares of the company’s stock worth $496,000 after purchasing an additional 1,838 shares during the period. AMF Tjanstepension AB raised its position in Kenvue by 187.3% in the 3rd quarter. AMF Tjanstepension AB now owns 120,477 shares of the company’s stock valued at $2,787,000 after purchasing an additional 78,540 shares in the last quarter. Handelsbanken Fonder AB boosted its stake in shares of Kenvue by 2.7% in the 3rd quarter. Handelsbanken Fonder AB now owns 720,962 shares of the company’s stock valued at $16,676,000 after buying an additional 19,051 shares during the period. Finally, Czech National Bank grew its position in shares of Kenvue by 6.9% during the third quarter. Czech National Bank now owns 390,139 shares of the company’s stock worth $9,024,000 after buying an additional 25,253 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several brokerages recently weighed in on KVUE. Royal Bank of Canada reiterated a “sector perform” rating and issued a $24.00 price target on shares of Kenvue in a research note on Monday. UBS Group decreased their price objective on shares of Kenvue from $24.00 to $23.00 and set a “neutral” rating for the company in a research report on Thursday, January 16th. JPMorgan Chase & Co. increased their target price on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Deutsche Bank Aktiengesellschaft downgraded Kenvue from a “buy” rating to a “hold” rating and decreased their price target for the stock from $25.00 to $24.00 in a report on Thursday, December 12th. Finally, Piper Sandler raised Kenvue from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $21.00 to $26.00 in a research report on Monday, January 6th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and four have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $23.08.
Kenvue Price Performance
Shares of NYSE KVUE opened at $21.22 on Tuesday. The stock has a 50 day moving average of $21.90 and a two-hundred day moving average of $21.92. The stock has a market cap of $40.69 billion, a P/E ratio of 38.59, a P/E/G ratio of 2.05 and a beta of 1.45. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.
Kenvue (NYSE:KVUE – Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The company had revenue of $3.90 billion for the quarter, compared to the consensus estimate of $3.92 billion. During the same period last year, the firm posted $0.31 EPS. Kenvue’s revenue for the quarter was down .4% on a year-over-year basis. On average, research analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.
Kenvue Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be given a dividend of $0.205 per share. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a yield of 3.86%. Kenvue’s payout ratio is 149.09%.
Kenvue Profile
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Further Reading
- Five stocks we like better than Kenvue
- What Makes a Stock a Good Dividend Stock?
- How to Invest in Small Cap Stocks
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- These Are the Dividend Stocks Insiders Bought in January
- What is a Bond Market Holiday? How to Invest and Trade
- How the ‘No Buy’ Trend of 2025 Is Boosting These 3 Stocks
Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.